| Autor: |
Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Amir Ghaemi, Mohammad Reza Zali |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Virology Plus, Vol 3, Iss 4, Pp 100167- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2667-0380 |
| DOI: |
10.1016/j.jcvp.2023.100167 |
| Popis: |
The pandemic of 2019 coronavirus disease (COVID-19) has become a world public health challenge. A new member of Coronaviridae family, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative of COVID-19. Although SARS-CoV-2 infection has a direct impact on the respiratory function, extra-respiratory complications such as liver damage have been reported in some cases. However, the exact mechanisms of liver injury in SARS-CoV-2 infection remain largely unexplored. It has also been suggested that patients with pre-existing liver disease are significantly influenced by COVID-19. Considering the double burden of chronic liver diseases and SARS-CoV-2 on health systems, investigating the interrelationship between COVID-19 and underlying liver disease and providing clear recommendations on treatment are very much needed.Viral hepatitis is recognized as one of the substantial risk factors for chronic liver diseases. Hepatitis B virus (HBV) is a main cause of liver failure, cirrhosis and hepatocellular carcinoma (HCC). Since both HBV and SARS-CoV-2 affect liver physiology, investigating the possible interactions and effects of SARS-CoV-2/HBV co-infection is increasingly important. This review highlighted the molecular and clinical consequences of SARS-CoV-2/HBV co-infection. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
